Infigratinib 75 mg Daily Dose, 25 mg Oral Capsule 63 Count Pack
RxNorm 2551211

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 2551211 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: infigratinib 75 mg Daily Dose, 25 mg Oral Capsule 63 Count Pack.

The following semantic concepts and normalized strings are associated with this clinical entity:

SY
Infigratinib 75 mg Daily Dose Carton, 2 Blister Cards, 42 & 21 Capsules Each
AUI:12641351
View
PSN
Infigratinib 75 mg Daily Dose, 25 mg Oral Capsule 63 Count Pack
AUI:12641353
View
GPCK
{63 (infigratinib 25 mg Oral Capsule) } Pack
AUI:12641347
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SYPrescribable

Synonym (SY):
Infigratinib 75 mg Daily Dose Carton, 2 Blister Cards, 42 & 21 Capsules Each
(Atom ID: 12641351)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
infigratinib 75 MG Daily Dose Carton, 2 Blister Cards, 42 & 21 Capsules Each
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2551211
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12641351
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SY
Synonym (Synonym of another TTY, given for clarity.)
Source Code
2551211
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
PSNPrescribable

Prescribable Name (PSN):
Infigratinib 75 mg Daily Dose, 25 mg Oral Capsule 63 Count Pack
(Atom ID: 12641353)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
infigratinib 75 MG Daily Dose, 25 MG Oral Capsule 63 Count Pack
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2551211
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12641353
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
PSN
Prescribable Name (Synonym of another TTY, given for clarity and for display purposes in electronic prescribing applications. Only one PSN per concept.)
Source Code
2551211
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.
GPCKPrescribable

Generic Pack (GPCK):
{63 (infigratinib 25 mg Oral Capsule) } Pack
(Atom ID: 12641347)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
{63 (infigratinib 25 MG Oral Capsule) } Pack
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
2551211
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
12641347
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
GPCK
Generic Pack ({# (Ingredient + Strength + Dose Form) / # (Ingredient + Strength + Dose Form)} Pack)
Source Code
2551211
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Technical Attributes & Logic

RXN HUMAN DRUG
US
Drug available for use in Humans

Patient Education

Infigratinib


Infigratinib is used in adults who have received previous therapy to treat a certain type of cholangiocarcinoma (bile duct cancer) that has spread to nearby tissues or other parts of the body and cannot be removed by surgery. Infigratinib is in a class of medications called kinase inhibitors. It works by blocking the action of the abnormal protein that signals cancer cells to multiply. This helps stop or slow the spread of cancer cells.
[Learn More]


* Please review the disclaimer below.